Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing

On July 28, 2020 Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna Zentaris" or the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, reported that on July 27, 2020, the Company received notice from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon a closing bid price of less than $1.00 per share for the Company’s common stock for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5550(a)(2) (the "Rule") (Press release, AEterna Zentaris, JUL 28, 2020, View Source [SID1234562498]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a grace period of 180 calendar days, through January 25, 2021, to evidence compliance with the Rule. To evidence compliance with the Rule, the Company must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days, but generally not more than 20 consecutive business days, on or before January 25, 2021. In the event the Company does not timely evidence compliance with the Rule, the Company may be eligible for an additional 180-day grace period or may face delisting. In the latter case, the Company would be entitled to request a hearing before the Nasdaq Hearings Panel, which request would stay any delisting action by the Staff pending completion of the hearing process.

Nasdaq’s notice has no immediate effect on the listing of the Company’s common shares on Nasdaq and does not otherwise impact the Company’s listing on the Toronto Stock Exchange. The Company is considering the options available to it to evidence compliance with the Rule prior to the expiration of the grace period.

In addition, as previously disclosed via Form 6-K filed with the Securities and Exchange Commission on July 1, 2020, Aeterna Zentaris priced an approximate $12 million public offering of its common stock and warrants, pursuant to which the Company ultimately raised approximately $10.5 million in net proceeds.

As a result of the offering, the Company believes it has stockholders’ equity of at least $2.5 million as of the date of this filing and thereby satisfies the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(3). The Company is awaiting Nasdaq’s formal confirmation of such compliance and will provide additional disclosure upon receipt of a compliance determination from the Staff.

LabCorp Announces 2020 Second Quarter Results

On July 28, 2020 LabCorp (or the Company) (NYSE: LH) reported results for the second quarter ended June 30, 2020 (Press release, LabCorp, JUL 28, 2020, View Source [SID1234562428]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to bring the full power of our combined diagnostics and drug development capabilities against this virus, applying our scientific expertise and ingenuity across all aspects of testing, treatments, and vaccines," said Adam Schechter, chairman and CEO, LabCorp. "During the second quarter, we delivered solid performance across the company despite the impact of the pandemic. I continue to be impressed with how quickly our teams have rallied to confront each and every challenge put before them, and I want to thank our 65,000 employees, as their efforts have been heroic during this difficult time."

Consolidated Results

Second Quarter Results

Revenue for the quarter was $2.77 billion, a decrease of (3.9%) from $2.88 billion in the second quarter of 2019. The decrease in revenue was due to a (5.4%) decline of organic revenue, (0.3%) from the disposition of a business, and (0.1%) from unfavorable foreign currency translation, partially offset by 1.9% from acquisitions. The (5.4%) decline of organic revenue was due to the pandemic, which reduced the Company’s organic Base Business by (20.9%), partially offset by COVID-19 Testing of 15.4%. "Base Business" includes the Company’s business operations except for molecular and serology COVID-19 testing ("COVID-19 Testing"). The decline in organic Base Business includes the lower Medicare and Medicaid pricing as a result of PAMA of (0.5%).

Operating income for the quarter was $297.7 million, or 10.8% of revenue, compared to $335.7 million, or 11.6%, in the second quarter of 2019. The decrease in operating income and margin was primarily due to the reduction in the Base Business (due to the pandemic and ($14.0) million from PAMA) and higher personnel costs (primarily driven by merit increases), partially offset by COVID-19 Testing and LaunchPad savings. The Company recorded restructuring charges, special items, and amortization, which together totaled $83.0 million in the quarter, compared to $111.2 million during the same period in 2019. Adjusted operating income (excluding amortization, restructuring charges, and special items) for the quarter was $380.7 million, resulting in a 13.8% adjusted operating margin, compared to $446.9 million, or 15.5%, in the second quarter of 2019. The ($66.1) million decline in adjusted operating income and (180) basis point decline in adjusted operating margin were primarily due to the reduction in the Base Business (due to the pandemic) and higher personnel costs, partially offset by the increase in COVID-19 Testing and LaunchPad savings.

Net earnings for the quarter were $231.6 million, compared to $190.4 million in the second quarter of 2019. Diluted EPS were $2.37 in the quarter, an increase of 22.8% over $1.93 in the same period in 2019. The increase in net earnings and diluted EPS in the quarter was primarily due to the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) Emergency Funding, which increased net earnings and diluted EPS by $55.9 million and $0.42 per share, respectively. Adjusted EPS (excluding amortization, restructuring charges, and special items) were $2.57 in the quarter, a decrease of (12.3%) compared to $2.93 in the second quarter of 2019 due to the pandemic. Adjusted EPS exclude the impact from the CARES Act Emergency Funding.

Operating cash flow for the quarter was $370.7 million, compared to $253.5 million in the second quarter of 2019. The increase in operating cash flow was due to higher cash earnings, partially offset by higher working capital. For the second quarter of 2020, cash earnings included the CARES Act and benefited from income and payroll tax deferrals, while working capital was negatively impacted by an increase in COVID-19 Testing related supplies and accounts receivable. Capital expenditures totaled $98.5 million, compared to $85.2 million a year ago. This increase was driven by expenditures associated with the increase in COVID-19 Testing capacity of $20.1 million. As a result, free cash flow (operating cash flow less capital expenditures) was $272.2 million, up from $168.3 million in the second quarter of 2019.

At the end of the quarter, the Company’s cash balance and total debt were $557.0 million and $6.2 billion, respectively. During the quarter, the Company invested $11.3 million on acquisitions.

Year-To-Date Results

Revenue was $5.59 billion, a decrease of (1.4%) from $5.67 billion in the first half of last year. The decrease in revenue was due to a (3.6%) decline of organic revenue, (0.4%) from the disposition of a business, and (0.1%) from unfavorable foreign currency translation, partially offset by 2.6% from acquisitions. The (3.6%) decline of organic revenue was due to the pandemic, which reduced the Company’s organic Base Business by (11.7%), partially offset by COVID-19 Testing of 8.1%. The decline in the organic Base Business includes the negative impact from PAMA of (0.6%).

Operating income was $105.1 million, or 1.9% of revenue, compared to $653.9 million, or 11.5%, in the first half of 2019. The decrease in operating income and margin was primarily due to the pandemic (including the impairments to goodwill and other assets), higher personnel costs (primarily driven by merit increases and one additional payroll day), and ($33.0) million from PAMA, partially offset by LaunchPad savings. The Company recorded restructuring charges, special items, impairments, and amortization, which together totaled $641.5 million in the first half of 2020, compared to $204.4 million during the same period in 2019. This increase includes COVID-19 related impairments on goodwill and other assets of $437.4 million, or approximately 3.7% of the Company’s total goodwill and intangible assets that the Company recorded in the first quarter of 2020. In addition, the Company recorded $34.0 million of other COVID-19 related costs. Adjusted operating income (excluding amortization, restructuring charges, special items, and impairments) for the first half of 2020 was $746.6 million, resulting in a 13.3% adjusted operating margin, compared to $858.3 million, or 15.1%, in the first half of 2019. The ($111.7) million decline in adjusted operating income and (180) basis point decline in adjusted operating margin were primarily due to the reduction in the Base Business (due to the pandemic) and higher personnel costs, partially offset by the increase in COVID-19 Testing and LaunchPad savings.

Net losses in the first half of 2020 were ($85.6) million, compared to net earnings of $376.0 million in the first half of 2019. Diluted EPS were ($0.88) in the first half of 2020 compared to $3.79 in the same period in 2019. Net losses and diluted EPS in the first six months of 2020 include the CARES Act Emergency Funding, which improved net losses and diluted EPS by $55.9 million and $0.42 per share, respectively. Adjusted EPS (excluding amortization, restructuring charges, special items, and impairments) were $4.94 in the first half of 2020, a decrease of (11.0%) compared to $5.55 in the first half of 2019 due to the pandemic. Adjusted EPS exclude the impact from the CARES Act Emergency Funding.

Operating cash flow was $574.5 million, compared to $419.3 million in the first half of 2019. The increase in operating cash flow was due to higher cash earnings, partially offset by higher working capital. For the first six months of 2020, cash earnings included the CARES Act and benefited from income and payroll tax deferrals, while working capital was negatively impacted by an increase in COVID-19 Testing related supplies and accounts receivable. Capital expenditures totaled $205.1 million, compared to $179.4 million during the same period in 2019. This increase was primarily driven by expenditures associated with the increase in COVID-19 Testing capacity of $22.5 million. As a result, free cash flow (operating cash flow less capital expenditures) was $369.4 million, compared to $239.9 million in the first half of 2019.

Second Quarter Segment Results

The following segment results exclude amortization, restructuring charges, special items, and unallocated corporate expenses.

LabCorp Diagnostics

Revenue for the quarter was $1.69 billion, a decrease of (3.9%) from $1.76 billion in the second quarter of 2019. The decrease in revenue was due to a (4.9%) decline in organic revenue and (0.1%) from unfavorable foreign currency translation, partially offset by 1.1% from acquisitions. The (4.9%) decline in organic revenue was due to a (30.1%) decline of the organic Base Business (due to the pandemic), partially offset by 25.2% from COVID-19 Testing. The (30.1%) decline of the organic Base Business includes a (0.8%) negative impact from PAMA and a (1.2%) reduction due to the September 2019 non-renewal of the BeaconLBS – UnitedHealthcare contract pertaining to the Florida market.

Total volume (measured by requisitions) decreased by (19.5%) as organic volume declined by (20.7%), partially offset by acquisition volume of 1.2%. The decline in organic volume includes a (35.3%) reduction in the Base Business (due to the pandemic), partially offset by increased demand for COVID-19 Testing of 14.6%. The organic Base Business volumes improved throughout the quarter, while at the same time COVID-19 Testing demand continued to grow. For June, daily organic volume increased approximately 6% as compared to the prior year, as the (17%) decline in the organic Base Business was more than offset by COVID-19 Testing volume of approximately 23%. While total volume declined (19.5%), price / mix increased by 15.6% due to COVID-19 Testing of 10.7% and the Base Business of 4.9%. The Base Business price includes the negative impact from PAMA of (0.8%) and the non-renewal of the BeaconLBS contract of (1.2%).

Adjusted operating income for the quarter was $308.8 million, or 18.2% of revenue, compared to $345.4 million, or 19.6%, in the second quarter of 2019. The ($36.6) million decline in adjusted operating income and (140) basis point decline in adjusted operating margin were primarily due to the reduction in the Base Business (due to the pandemic) and higher personnel costs, partially offset by the increase in COVID-19 Testing and LaunchPad savings. The Company remains on track to deliver approximately $200 million of net savings from its three-year Diagnostics LaunchPad initiative by the end of 2021.

Covance Drug Development

Revenue for the quarter was $1.09 billion, a decrease of (2.9%) from $1.13 billion in the second quarter of 2019. The decrease in revenue was due to a (5.2%) decline in organic revenue, (0.7%) from the disposition of a business, and (0.1%) from unfavorable foreign currency translation, partially offset by a 3.1% benefit from an acquisition. The decline in organic revenue was primarily due to the negative impact from the pandemic, partially offset by a 1.1% increase from molecular COVID-19 testing through its Central Laboratories business. The pandemic continues to cause delays in clinical trial progression and associated testing, reductions in investigator site access, as well as interruptions to the supply chain particularly impacting the nonclinical business unit.

Adjusted operating income for the quarter was $112.7 million, or 10.3% of revenue, compared to $141.7 million, or 12.6%, in the second quarter of 2019. The ($29.0) million decrease in adjusted operating income and (230) basis point decrease in adjusted operating margin were primarily due to the negative impact from the pandemic and higher personnel costs, partially offset by molecular COVID-19 testing and LaunchPad savings. The Company remains on track to deliver approximately $150 million of net savings from its three-year Drug Development LaunchPad initiative by the end of 2020.

Net orders and net book-to-bill during the trailing twelve months were $6.11 billion and 1.32, respectively. Backlog at the end of the quarter was $11.79 billion compared to $11.30 billion last quarter, and the Company expects approximately $4.0 billion of its backlog to convert into revenue in the next twelve months.

Outlook for 2020

Given the continued unpredictability pertaining to the COVID-19 pandemic and the corresponding government restrictions and customer behavior, there are a wide-range of feasible financial outcomes. As a result, the Company continues to not provide 2020 guidance. While LabCorp’s Base Business continues to be negatively impacted by the COVID-19 pandemic, the Company’s outlook has improved across the enterprise.

In LabCorp Diagnostics, demand for its Base Business continues to be below the Company’s historical levels; however, this business has been steadily recovering from its trough in April, while at the same time COVID-19 Testing continues to grow. To date, LabCorp has performed more than 8.5 million molecular COVID-19 tests as well as more than 2 million serology COVID-19 tests. The Company’s current molecular COVID-19 testing capacity is approximately 180,000 tests per day and growing.

In Covance Drug Development, while it is expected that the pandemic will continue to negatively impact its business, this impact is expected to subside throughout the year through continuing to work on projects supporting global vaccine and treatment development, with additional support from growth of COVID-19 Testing.

As previously announced, the Company instituted numerous actions to help mitigate the financial impact from the COVID-19 pandemic, which included furloughs, reduced hours, and the suspension of discretionary merit adjustments and 401(k) contributions. In response to LabCorp’s improved outlook, the Company has been resuming regular work schedules and is proceeding with merit adjustments and will retroactively reinstate 401(k) contributions.

Use of Adjusted Measures

The Company has provided in this press release and accompanying tables "adjusted" financial information that has not been prepared in accordance with GAAP, including adjusted net income, adjusted EPS (or adjusted net income per share), adjusted operating income, adjusted operating margin, free cash flow, and certain segment information. The Company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the Company’s operational performance. The Company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in evaluating operating results and trends, and growth and shareholder returns, as well as in comparing the Company’s financial results with the financial results of other companies. However, the Company notes that these adjusted measures may be different from and not

directly comparable to the measures presented by other companies. Reconciliations of these non-GAAP measures to the most comparable GAAP measures are included in the tables accompanying this press release.

The Company today is providing an investor relations presentation with additional information on its business and operations, which is available in the investor relations section of the Company’s website at View Source Analysts and investors are directed to the website to review this supplemental information.

A conference call discussing LabCorp’s quarterly results will be held today at 9:00 a.m. EDT and is available by dialing 877-898-8036 (720-634-2811 for international callers). The access code is 2597361. A telephone replay of the call will be available through August 11, 2020, and can be heard by dialing 855-859-2056 (404-537-3406 for international callers). The access code for the replay is 2597361. A real-time webcast of LabCorp’s quarterly conference call on July 28, 2020, will be available at LabCorp Investor Relations website beginning at 9:00 a.m. EDT. This webcast will be archived and accessible through July 14, 2021.

Sunesis Announces Proposed Public Offering of Common Stock

On July 28, 2020 Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) reported that it intends to offer and sell, subject to market and other conditions, shares of its common stock, in an underwritten public offering (Press release, Sunesis, JUL 28, 2020, View Source [SID1234562453]). There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering. Sunesis also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering to cover over-allotments, if any. Sunesis anticipates using the net proceeds from the proposed offering to fund ongoing development of PDK1 inhibitor SNS-510 and general corporate purposes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oppenheimer & Co. Inc. is acting as the sole book-running manager in this proposed offering.

The securities described above are being offered by Sunesis pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC"), originally filed with the SEC on June 8, 2017 and which the SEC declared effective on November 21, 2017. A preliminary and final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website at View Source Copies of the preliminary and final prospectus supplements and the accompanying prospectus relating to this offering, when available, may be obtained on the SEC’s website or from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, by telephone at 212-667-8055, or by email at [email protected].

Novocure Announces Recipients of 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

On July 28, 2020 Novocure (NASDAQ:NVCR) reported the recipients of the AACR (Free AACR Whitepaper)-Novocure Grants for Tumor Treating Fields Research program (Press release, NovoCure, JUL 28, 2020, View Source [SID1234562473]). The program represents a joint effort between Novocure and the American Association for Cancer Research (AACR) (Free AACR Whitepaper) to promote and support innovative research on Tumor Treating Fields. The AACR (Free AACR Whitepaper) is the first and largest cancer research organization dedicated to accelerating the conquest of cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Such collaborations help to deepen the understanding of the mechanism of action and to accelerate the development of new treatment strategies. Extensive preclinical and clinical evidence provides the foundation upon which Novocure executes its strategy to advance Tumor Treating Fields through additional clinical research studies across multiple solid tumor types.

"Congratulations to the recipients of the AACR (Free AACR Whitepaper)-Novocure Grants for Tumor Treating Fields Research," said Asaf Danziger, Novocure’s Chief Executive Officer. "We value our ongoing partnership with the AACR (Free AACR Whitepaper) as we continue to deepen our understanding of the mechanism of action of Tumor Treating Fields. We look forward to learning the outcomes of the impressive research planned by our grant recipients."

"The AACR (Free AACR Whitepaper) is thrilled to welcome its newest class of grant recipients, including the recipients of the AACR (Free AACR Whitepaper)-Novocure Grants for Tumor Treating Fields," said Mitch Stoller, the AACR (Free AACR Whitepaper)’s Chief Philanthropic Officer. "Our continued partnership with Novocure has played a pivotal role in providing crucially needed resources to scientists on the leading edge of discovery. The innovative research supported by these grants will contribute to our understanding of Tumor Treating Fields, and may lead to the identification of new and exciting applications for this emerging technology."

2020 AACR (Free AACR Whitepaper)-Novocure Career Development Awards for Tumor Treating Fields Research

Narasimha Kumar Karanam, Ph.D., University of Texas Southwestern Medical Center
"Harnessing E2F-Rb-CDK4/6 axis for novel combination therapy with TTFields"
Chirag B. Patel, M.D., Ph.D., Stanford University
"Increasing glioblastoma cell membrane permeability with TTFields"
2020 AACR (Free AACR Whitepaper)-Novocure Tumor Treating Fields Research Grants

Carsten Hagemann, Ph.D., Universitätsklinikum Würzburg, Germany
"Overcoming the blood brain barrier drug delivery hurdle with TTFields"
Sandeep Mittal, M.D., FRCSC, FACS, Virginia Polytechnic Institute
"Epigenetic modifications induced by TTFields in patient-derived GBM cells"
Debabrata Saha, Ph.D., University of Texas Southwestern Medical Center
"Evaluating efficacy of TTFields and radiotherapy in preclinical tumor model"
David D. Tran, M.D., Ph.D., University of Florida College of Medicine
"Molecular mechanism of resistance to Tumor Treating Fields in glioblastoma"
Christopher Douglas Willey, M.D., Ph.D., University of Alabama at Birmingham
"Exploring Novo-TTF in advanced patient derived GBM models with multi-omics"

ivy brain tumor center and bridgebio pharma’s qed therapeutics announce dosing of first patient in investigator-initiated phase 0/2 clinical trial of infigratinib in recurrent glioblastoma

On July 28, 2020 Ivy Brain Tumor Center at Barrow Neurological Institute reported that the first patient has been dosed in an investigator-initiated Phase 0/2 clinical trial of infigratinib in recurrent high-grade glioma driven by FGFR genetic alterations (Press release, BridgeBio, JUL 28, 2020, View Source [SID1234576226]). Infigratinib is an investigational, orally administered, FGFR1-3 selective tyrosine kinase inhibitor being developed by BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate company QED Therapeutics, Inc.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The investigator-initiated Phase 0/2 trial is designed to confirm drug effects within days of exposure, and only to continue dosing when the drug is active in a patient’s own tumor. The primary objective of the Phase 0 arm is to assess how effectively infigratinib can cross the blood-brain barrier – the most significant obstacle to developing new, effective therapies for aggressive brain tumors like glioblastoma. Patients with successful tumor penetration will receive infigratinib long-term in a Phase 2 expansion arm of the trial. The primary endpoint of the expansion phase is progression-free survival rate at six months. The study will also measure how well infigratinib is impacting its molecular target in each patient’s tumor.

FGFR (fibroblast growth factor receptor) genetic alterations have been shown to spur growth in malignant tumors. Five to seven percent of glioblastoma patients’ tumors are driven by FGFR signaling. During the trial screening process, the patient’s tumor tissue from prior surgery will be tested for the FGFR-TACC3 fusion gene or mutations in FGFR1 and FGFR3 genes. Patients with tumors that have these fusions or mutations are eligible for this study.

"In the preclinical studies, our pharmacokinetics program at the Ivy Brain Tumor Center tested seven FGFR inhibitors for their ability to cross the blood-brain barrier. Infigratinib was one of the most promising agents," said Shwetal Mehta, Ph.D., deputy director of the Ivy Brain Tumor Center.

"Infigratinib was previously tested in an uncontrolled Phase 2 study for recurrent high-grade gliomas," said Nader Sanai, M.D., director of the Ivy Brain Tumor Center. "The results were intriguing, but inconclusive. This Ivy Phase 0/2 trial seeks to provide direct biological evidence of drug effects in individual patients, allowing us to understand which glioblastoma patients may benefit from infigratinib."

"The launch of this investigator-initiated trial is an exciting step in the study of infigratinib for patients with recurrent, high-grade glioma," said Susan Moran, M.D., M.S.C.E., chief medical officer of QED Therapeutics. "We anticipate this study being conducted by the Ivy Center will generate valuable information on the ability of infigratinib to reach brain tumors, which is a critical first step in evaluating whether infigratinib, alone or in combination, could potentially provide a therapeutic option for patients with this dire disease."